Lauro Guerrero
Optometrist · Harlingen, TXNPI 1902834963
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $97,080 of the $132,648 with a category attached, or 73.2%. 31 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 43.0% of the total. Among optometrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 915 payments — averaging $144.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$57K
- AbbVie$38K
- Aerie Pharmaceuticals, Inc.$14K
- Oyster Point Pharma, Inc.$7K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- Shire North American Group Inc$3K
- plus $12K from 25 others
What the payments were for
- Speaking & faculty fees$97,08073%
- Travel & lodging$8,1236%
- Food & beverage$27,21521%
- Education$1850%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 201 | $56,976 |
| AbbVie(2 entities) | 203 | $37,536 |
| Aerie Pharmaceuticals, Inc. | 49 | $13,705 |
| Oyster Point Pharma, Inc. | 71 | $6,520 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 42 | $2,759 |
| Shire North American Group Inc | 15 | $2,679 |
| Alcon | 52 | $1,997 |
| Novartis | 92 | $1,694 |
| Coopervision Inc. | 40 | $1,133 |
| Tarsus Pharmaceuticals, Inc. | 30 | $986 |
| Biotissue Holdings Inc. | 12 | $798 |
| Dompe US, Inc. | 19 | $780 |
| Glaukos Corporation | 6 | $732 |
| Sun Pharmaceutical Industries Inc. | 18 | $652 |
| Eyevance Pharmaceuticals LLC | 20 | $528 |
| Genentech USA, Inc. | 5 | $324 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $296 |
| Regeneron Healthcare Solutions, Inc. | 5 | $290 |
| Harrow Eye, LLC | 3 | $278 |
| Apellis Pharmaceuticals, Inc. | 3 | $268 |
| Rxsight Inc | 2 | $267 |
| Sight Sciences, Inc. | 3 | $260 |
| Merz Pharmaceuticals, LLC | 2 | $202 |
| Kala Pharmaceuticals, Inc. | 4 | $168 |
| Tearlab Corp | 4 | $158 |
| Mallinckrodt Hospital Products Inc. | 2 | $152 |
| Astellas Pharma US Inc | 1 | $150 |
| LKC Technologies, Inc. | 1 | $137 |
| Eyepoint US, Inc. | 3 | $117 |
| Amgen | 1 | $86 |
| Thea Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$132,648 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 870 | $1,223,018 |
| RestasisCyclosporine | 255 | $303,186 |
| XdemvyLotilaner | 149 | $289,901 |
| LumiganBimatoprost | 329 | $204,442 |
| MieboPerfluorohexyloctane/Pf | 184 | $155,612 |
| Cyclosporine | 121 | $73,301 |
| TyrvayaVarenicline Tartrate | 32 | $41,983 |
| CombiganBrimonidine Tartrate/Timolol | 47 | $21,417 |
| RhopressaNetarsudil Mesylate | 37 | $19,803 |
| VyzultaLatanoprostene Bunod | 38 | $16,957 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 79 | $14,479 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 33 | $8,912 |
| Latanoprost | 591 | $7,990 |
| EysuvisLoteprednol Etabonate | 16 | $7,562 |
| Alphagan PBrimonidine Tartrate | 11 | $5,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $56,976 | $1,395,5871,092 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $37,536 | $534,831642 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $986 | $289,901149 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $6,520 | $41,98332 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $13,705 | $19,80337 claims |
| AlconSimbrinza | $1,997 | $8,91233 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $168 | $7,56216 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $2,759 | $3,01623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Harlingen
- Derek CunninghamAustin$940K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Luis RojasMcKinney$309K
- Emile FadelAustin$225K
- Bridgitte LeeHouston$222K
- Phillip BrunsonHouston$214K
- Jill AutryBellaire$171K
- Stacie VirdenWaco$164K
- Richard PotvinBurleson$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.